http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8980955-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d185bec53204524c5919125b97f259be http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcff8bd6fddb1edb3b803650a94eaad7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-93 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 |
| filingDate | 2011-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9666cfa6e5d68fe551ac347b3fb89f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dfe3205ce977e830f0d63018893f370 |
| publicationDate | 2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8980955-B2 |
| titleOfInvention | Small molecule inhibitors of replication protein A that also act synergistically with cisplatin |
| abstract | Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC 50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11541027-B2 |
| priorityDate | 2010-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 120.